Cambrex, a global CDMO, is investing $120 million to expand its U.S. operations for API development and manufacturing. The investment reflects the company’s efforts to meet the growing demand for peptide therapeutics and critical therapies, and ensure reliable, high-quality manufacturing in the U.S.

The $120 million investment will support a 40% increase in the Charles City, IA site’s large-scale manufacturing capacity, reaching nearly one million liters. The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain security and resilience, and Cambrex will play a key role. We are seeing very strong demand from our customers to partner with Cambrex to utilize this expanded capacity,” commented Thomas Loewald, CEO of Cambrex.

This investment builds on Cambrex’s expansions over the past five years, including:

The addition of highly potent API and large-scale manufacturing capacity in Charles City, IA.

New, state-of-the-art labs, clinical and small-to-medium volume commercial manufacturing capacity for commercial therapies targeting rare diseases and orphan designations, in High Point, NC.

Expanded capabilities and new GMP manufacturing capacity for peptide therapeutics in Waltham, MA.